Click for next page ( 38

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 37
REFERENCES Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proceedings of the National Academy of Sciences USA 90~6~:2291-2294. ACIP (Advisory Committee on Immunization Practices). 1994. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices. MIRIER (Morbidity and Mortality Weekly) 43(RR-1~:33 p. Bioport Corporation. 1999. U.S. License No. 1260. Anthrax Vaccine Adsorbed, Package Insert. Brachman PS, Gold H. Plotkin S. Fekety FR, Werrin M, Ingraham NR. 1962. Field evaluation of a human anthrax vaccine. American Journal of Public Health 52:632-645. Brachman P. Friedlander A. 1999. Anthrax. In: Plotkin SA, Orenstein WA, eds. Vaccines. Vol. Chapter 24. Third ed. Philadelphia: WB Saunders Company, 629-637. Caserta V. 2000 (October 31~. Anthrax Vaccine Expert Committee (AVEC) and VAERS. Presentation at: Institute of Medicine Committee to Review the CDC Anthrax Vacine Safety and Eff cacy Research Program. Meeting I. Washington, D.C. Dixon TC, Meselson M, Guillemin J. Hanna PC. 1999. Anthrax. New England Journal of Medicine 341(~1 19:815- 826. FDA (Food and Drug Administration). 1999. New drug and biological drug products; evidence needed to demonstrate efficacy of new drugs for use against lethal or permanently disabling toxic substances when efficacy studies in humans ethically cannot be conducted. Federal Register 64~192~:53960-53970. Friedlander AM, Pittman PR, Parker GW. 1999. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAM4 282~22~:2104-2106. Fukuda K, Nisenbaum R. Stewart G. Thompson WW, Robin L, Washko RM, Noah DL, Barrett DlI, Randall B. Herwaldt BL, Mawle AC, Reeves WC. 1998. Chronic multisymptom illness affecting Air Force veterans of the Gulf War [see comments]. JAM;4 280~11~:981-988. Gladstone GP. 1946. Immunity to anthrax protective antigen present in cell-free culture filtrates. British Journal of Experimental Pathology 27:394-418. Hotopf M, David A, Hull L, Ismail K, Unwin C, Wessely S. 2000. Role of vaccinations as risk factors for ill health in veterans ofthe Gulf War: cross sectional study . British Medical Journal 320~7246~:1363-1367. Inglesby TV. 1999. Anthrax: a possible case history. Emerging Infectious Diseases 5~4~:556-560. IOM (Institute of Medicine). 1996. Health Consequences of Service D?vring the Persian Gulf War: Recommendations for Research and information Systems. Washington, D.C.: National Academy Press. IOM. 2000a. Gulf War and Health. Washington, D.C.: National Academy Press. IOM. 2000b. Safety of the Anthrax Vaccine: a Letter Report. Washington, DC: National Academy Press. Iowa Persian Gulf Study Group. 1997. Self-reported illness and health status among Gulf War veterans. A population-based study. JAM4 277~3~:238-245. Ivins B. Fellows P. Pitt L, Estep J. Farchaus J. Friedlander A, Gibbs P. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13 ~ 18~: 1779- 1784. Jackson PJ, Hugh-Jones ME, Adair DM, Green G. Hill KK, Kuske CR, Grinberg LM, Abramova FA, Keim P. 1998. PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: the presence of multiple Bacillus anthracis strains in different victims. Proceedings of the National Academy of Sciences USA 95~33: 1224-1229. Little SF, Ivins BE. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes and Infection 1 (2~: 1 3 1 - 139. Marshall E. 2000. Bioterrorism. DOD retreats on plan for anthrax vaccine. Science 289~54789:382-383. Mazzuchi JF, Claypool RG, Hyams KC, Trump D, Riddle J. Patterson RE, Bailey S. 2000. Protecting the health of U.S. military forces: a national obligation. Aviation, Space, and Environmental Medicine 71~33:260-265. Meselson M, Guillemin J. Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266~51884:1202-1208. Mootrey GT. 2000 (October 31~. Vaccine Adverse Events Reporting System (VAERS) and anthrax vaccine. Presentation at: Institute of Medicine Committee to Review the CDC Anthrax Vaccine Safety and Effcacy Research Program. Meeting I. Washington, D.C. 37

OCR for page 37
38 / CDC ANTHRAX VACCINE SAFETY & EFFICACY RESEARCH PROGRAM Myers R. 2001 (January 29~. Components of the anthrax vaccine absorbed and contrast with Merck vaccine. Presentation at: Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthropic Vaccine. Meeting II. Washington, D.C. Pittman PR, Kim-Ahn G. Pifat DY, et al. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route comparison study in humans. Submitted for publication. Presidential Advisory Committee on Gulf War Veterans' Illnesses: Final Report. 1996. Washington, D.C.: U.S. Government Printing Office. Raub W. Deputy Assistant Secretary for Science Policy, Department of Health and Human Services. 1999. Federal policies on investigational new drugs. Statement at the November 9, 1999, hearing of the Subcommittee on National Security, Veterans Affairs and International Relations, Committee on Government Reform, U.S. House of Representatives. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. VAERS Working Group. Vaccine 17~224:2908-2917. Strom BL. 2000. What is pharmacoepidemiology? In: Strom BL (ed.), Pharmacoepidemiology. Third ed. West Sussex, England: John Wiley & Sons, 3-15. Tilson H. 1992. Pharmacosurveillance: public health monitoring of medication. In: Halperin W. Baker EL, Monson RR (Consulting Ed.), Public Health Surveillance. New York: Van Nostrand Reinhold, 206-229. Turnbull PC. 1991. Anthrax vaccines: past, present and fixture. Vaccine 9~8~:533-539. Wright GG, Green TW, Kanode RG, Jr. 1954. Studies on immunity in anthrax. V. Immunizing activity of alum- precipitated protective antigen. Journal of immunology 73:387-391. Wright GG, Puziss M, Neely WB. 1962. Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. Journal of Immunology 83 :515- 22. Zilinskas RA. 1997. Iraq's biological weapons: the past as ~ture? JAMA 278~5~:418-424. Zoon KC. 1999 (September 29~. Letter to Bailey, S.